100 related articles for article (PubMed ID: 2968885)
1. A comparison of morning and bed-time ultralente administration when using multiple injections in adolescence.
Smith CP; Dunger DB; Mitten S; Hewitt J; Spowart K; Grant DB; Savage MO
Diabet Med; 1988; 5(4):352-5. PubMed ID: 2968885
[TBL] [Abstract][Full Text] [Related]
2. Early morning glycaemia and the metabolic consequences of delaying breakfast/morning insulin. A comparison of continuous subcutaneous insulin infusion and multiple injection therapy with human isophane or human ultralente insulin at bedtime in insulin-dependent diabetics.
Haakens K; Hanssen KF; Dahl-Jørgensen K; Vaaler S; Torjesen P; Try K
Scand J Clin Lab Invest; 1989 Nov; 49(7):653-9. PubMed ID: 2692136
[TBL] [Abstract][Full Text] [Related]
3. A comparison of human ultralente- and lente-based twice-daily injection regimens.
Tunbridge FK; Newens A; Home PD; Davis SN; Murphy M; Burrin JM; Alberti KG; Jensen I
Diabet Med; 1989 Aug; 6(6):496-501. PubMed ID: 2527130
[TBL] [Abstract][Full Text] [Related]
4. Human ultralente insulin: a comparison with porcine lente insulin as a twice-daily insulin in insulin-dependent diabetic patients with fasting hyperglycaemia.
Francis AJ; Hanning I; Alberti KG
Diabetes Res; 1986 Jun; 3(5):263-8. PubMed ID: 3527523
[TBL] [Abstract][Full Text] [Related]
5. Improvement in morning hyperglycaemia with basal human ultratard and prandial human actrapid insulin--a comparison of multiple injection regimens.
Davies RR; McEwen J; Moreland TA; Durnin C; Newton RW
Diabet Med; 1988 Oct; 5(7):671-5. PubMed ID: 2975553
[TBL] [Abstract][Full Text] [Related]
6. Improvement of basal hepatic glucose production and fasting hyperglycemia of type I diabetic patients treated with human recombinant ultralente insulin.
Riccio A; Avogaro A; Valerio A; Zappella A; Tiengo A; Del Prato S
Diabetes Care; 1994 Jun; 17(6):535-40. PubMed ID: 8082521
[TBL] [Abstract][Full Text] [Related]
7. Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime.
Rossetti P; Pampanelli S; Fanelli C; Porcellati F; Costa E; Torlone E; Scionti L; Bolli GB
Diabetes Care; 2003 May; 26(5):1490-6. PubMed ID: 12716810
[TBL] [Abstract][Full Text] [Related]
8. Split-mixed insulin regimen with human ultralente before supper and NPH (isophane) before breakfast in children and adolescents with IDDM.
Wolfsdorf JI; Laffel LM; Pasquarello C; Vernon A; Herskowitz RD
Diabetes Care; 1991 Nov; 14(11):1100-6. PubMed ID: 1797498
[TBL] [Abstract][Full Text] [Related]
9. Optimization of evening insulin dose in patients using the short-acting insulin analog lispro.
Ahmed AB; Mallias J; Home PD
Diabetes Care; 1998 Jul; 21(7):1162-6. PubMed ID: 9653613
[TBL] [Abstract][Full Text] [Related]
10. Comparison of two twice-daily insulin regimens: ultralente/soluble and soluble/isophane.
Ward GM; Simpson RW; Ward EA; Turner RC
Diabetologia; 1981 Oct; 21(4):383-6. PubMed ID: 7026334
[TBL] [Abstract][Full Text] [Related]
11. Overnight metabolic control with bedtime injection of intermediate-acting insulin or continuous subcutaneous insulin infusion.
Olsson PO; Arnqvist H; Von Schenck H; Ottosson AM
Diabetes Care; 1987; 10(6):702-6. PubMed ID: 3322726
[TBL] [Abstract][Full Text] [Related]
12. Human ultralente insulin.
Holman RR; Steemson J; Darling P; Reeves WG; Turner RC
Br Med J (Clin Res Ed); 1984 Mar; 288(6418):665-8. PubMed ID: 6421424
[TBL] [Abstract][Full Text] [Related]
13. The use of human ultralente is limited by great intraindividual variability in overnight plasma insulin profiles.
Lindström T; Olsson PO; Arnqvist HJ
Scand J Clin Lab Invest; 2000 Aug; 60(5):341-7. PubMed ID: 11003253
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and acceptance of two intensified conventional insulin therapy regimens: a long-term cross-over comparison.
Houtzagers CM; Berntzen PA; van der Stap H; van Maarschalkerweerd WW; Lanting P; Boen-Tan I; Heine RJ; van der Veen EA
Diabet Med; 1989 Jul; 6(5):416-21. PubMed ID: 2527678
[TBL] [Abstract][Full Text] [Related]
15. Prevention of early-morning hyperglycemia in IDDM patients with long-acting zinc insulin.
Parillo M; Mura A; Iovine C; Rivellese AA; Lavicoli M; Riccardi G
Diabetes Care; 1992 Feb; 15(2):173-7. PubMed ID: 1547673
[TBL] [Abstract][Full Text] [Related]
16. Effects of meal carbohydrate content on insulin requirements in type 1 diabetic patients treated intensively with the basal-bolus (ultralente-regular) insulin regimen.
Rabasa-Lhoret R; Garon J; Langelier H; Poisson D; Chiasson JL
Diabetes Care; 1999 May; 22(5):667-73. PubMed ID: 10332663
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the safety and effectiveness of human and bovine long-acting insulins.
Selam JL; Turner D; Woertz L; Eichner HL; Lauritano A; Charles MA
Diabetes Res; 1989 Nov; 12(3):131-4. PubMed ID: 2635094
[TBL] [Abstract][Full Text] [Related]
18. Comparison of basal and prandial insulin therapy in patients with secondary failure of sulphonylurea therapy.
Paterson KR; Wilson M; Kesson CM; Buchan M; Roberts M; Reith SB; Davidson E
Diabet Med; 1991 Jan; 8(1):40-3. PubMed ID: 1826243
[TBL] [Abstract][Full Text] [Related]
19. Improved postprandial metabolic control after subcutaneous injection of a short-acting insulin analog in IDDM of short duration with residual pancreatic beta-cell function.
Pampanelli S; Torlone E; Ialli C; Del Sindaco P; Ciofetta M; Lepore M; Bartocci L; Brunetti P; Bolli GB
Diabetes Care; 1995 Nov; 18(11):1452-9. PubMed ID: 8722069
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.
Lepore M; Pampanelli S; Fanelli C; Porcellati F; Bartocci L; Di Vincenzo A; Cordoni C; Costa E; Brunetti P; Bolli GB
Diabetes; 2000 Dec; 49(12):2142-8. PubMed ID: 11118018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
